資源描述:
《[精品][經典]調脂湯治療非酒精性脂肪肝臨床療效觀察.doc》由會員上傳分享,免費在線閱讀,更多相關內容在工程資料-天天文庫。
1、[經典]調脂湯治療非酒精性脂肪肝臨床療效觀察調脂湯治療非酒精性脂肪肝臨床療效觀察【摘?!磕康模禾接懻{脂湯治療非酒精性脂肪肝的臨床療效。方法:按診斷標準選擇非酒精性脂肪肝患者162例,隨機分為兩組,治療組、對照組各81例。治療組服用調脂湯;對照組服用東寶肝泰片,治療前后詳細記錄兩組患者評定指標,實驗完成后對數(shù)據(jù)進行整理分析。結果:治療組總體療效優(yōu)于對照組,兩組比較卩V0.05,差異有顯著性意義。其中,在降血脂方面,兩組治療前后組內比較具有明顯差異,PV0.05;但治療后兩組間比較無明顯差異,P>0.05;在改善肝功能方面,兩者血清ALT、AST下降存在明顯差異,P<0.05o結論:調
2、脂湯治療非酒精性脂肪肝療效明顯優(yōu)于東寶肝泰片,其機理可能是通過改善肝細胞功能及降血脂實現(xiàn)的。【關鍵詞】非酒精性脂肪肝;調脂湯TheobservingofclinicaleffectofTiaoZhiSouptreatingwithnon-alcoholicfatty1iverdisease?Auther:MiaoXiangdong;Correspond!ng:FuHuaicheng(HezeChinesemedicinehospitalShandongProvinceHeze274000)[Abstract]Goal:ToexploretheclinicaleffectofTiao
3、ZhiSoupontreatingthenon-alcoholicfattyliverdisease?Method:Accordingtothediagnosisstandard,choosingthenon-alcoholicfatty1iverpatient162examplesaltogether?Thepatientswererandomlydividedintotwogroups:Thetreatmentgroupandthecontrolgroup.Eachgrouphave81examples.ThetreatmentgroupwastreatedwithTiaoZh
4、iSoupandthecontrolgroupwastreatedwithDongbaoLiverPiece?Aroundthetreatment,therelatedindicatorsoftwogroupswererecordedindetail,inordtoreorganizatandanalysisthedataaftertheexperimentFinally:Theoverallcurativeeffectoftreatmentgroupissuperiortothecontrolgroup,卩〈0.05,bothwasthesignificantdifference
5、?0ntheaspectofreducingbloodlipids,twogroupsweretheobviousdifferencebeforetreatment,P〈0?05;Butafterthetreatment,thechangesoftwogroup'sbloodlipidswerenotobviousdifferent?,P〉0?05;Ontheaspectofimprovementliverfunction,bothbloodserumALT,ASTwereobviousdifference,P〈0.05.Conclusion:TiaoZhiSoupcurative
6、effectissuperiortotheDongbaoLiverPieceobviouslyontreatthenon-alcoholicfattyliver?Itsmechanismistoreducethebloodlipidsandimprovelivercellfunctionpossibility?[Keyword】Thenon-alcoholicfattyliverdisease;TiaoZhiSoup非酒精性脂肪性肝病(NAFLD)是指除外酒精和其他明確的損肝因素所致的,以彌漫性肝細胞大泡性脂肪變?yōu)橹饕卣鞯呐R床病理綜合征,包括單純性脂肪肝以及由其演變的脂肪性肝炎(
7、NASH)和肝硬化。隨著肥胖和糖尿病的發(fā)病率增加,NAFLD現(xiàn)已成為我國常見的慢性肝病之一,嚴重危害人體健康[1]。筆者根據(jù)非酒精性脂肪肝的中醫(yī)病因病機特點,以調脂湯為主治療該病,取得較好療效,現(xiàn)報告如下:1臨床資料1.1一般資料162例非酒精性脂肪肝患者均為我院門診就診患者,隨機分為兩組,治療組81例,男57例,女24例;年齡21~68歲,平均(44?2±7?6)歲;病程0.5-15年。B超分級:輕度19人,中度19人,重度3人。對照組81例,男51例,女30例;年